Drugs / LV009 Injection Infusion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07312630 | Sep 2025 → Sep 2026 overdue | adult acute lymphoblastic leukemia | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LV009 Injection Infusion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07312630 ↗ |
| Modality | Cell therapy | “Injection of CD19-Targeted Chimeric Antigen Receptor T Cells” NCT07312630 ↗ |
| Target | CD19 | “CD19-Targeted Chimeric Antigen Receptor T Cells” NCT07312630 ↗ |